:max_bytes(150000):strip_icc():focal(717x224:719x226)/kelly-ripa-mark-consuelos-live-2-080525-9e98d41d17134c0c9b0dac66dac4cc7a.jpg)
A new peptide designed by UK scientists prevents misfolding of alpha-synuclein, the protein linked to Parkinson’s and certain dementias, showing promise in animal models for stabilizing brain function and improving movement.
October 9, 2025
Source:
Technology Networks
New Approach Targets Key Parkinson’s Protein
Scientists from the University of Bath, with teams at Oxford and Bristol, have made a major advance by developing a peptide capable of preventing the dangerous misfolding of alpha-synuclein. This protein is heavily implicated in the development of Parkinson’s disease and some types of dementia, including Lewy body dementia (Alzheimer’s Association).
Misfolded alpha-synuclein accumulates in the brain, disrupting the function of neurons and weakening the release of dopamine, which leads to classic symptoms such as tremors, muscle rigidity, and cognitive decline. Until now, therapies addressing this process have been limited.
Keep up with the story. Subscribe to the PR+ free daily newsletter
Source:
SciTechDaily
Peptide Locks Protein in Healthy Shape
Designed for Precision
The new peptide was engineered to bind alpha-synuclein and hold it in its natural, helical structure. This structure is key to normal protein function and prevents the formation of harmful clumps. The researchers relied on rational design techniques to create a short, stable peptide that mimics natural processes within the brain. (Nature Chemistry)
Worm Model Success: Lab tests in a worm model of Parkinson’s disease showed the peptide enters brain-like cells, reduces protein buildup, and improves physical movement.
Potential for Broader Impact: The study’s success could lead to new classes of peptide-based drugs for neurodegenerative diseases.
Read More
Source:
Science Daily
Share this news:
